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REVIEW
Human haematopoietic stem cell development: from the embryo
to the dish
Andrejs Ivanovs1,2, Stanislav Rybtsov1, Elizabeth S. Ng3,4, Edouard G. Stanley3,4,5, Andrew G. Elefanty3,4,5,*
and Alexander Medvinsky1,*
ABSTRACT
Haematopoietic stem cells (HSCs) emerge during embryogenesis
and give rise to the adult haematopoietic system. Understanding
how early haematopoietic development occurs is of fundamental
importance for basic biology and medical sciences, but our
knowledge is still limited compared with what we know of adult
HSCs and their microenvironment. This is particularly true for human
haematopoiesis, and is reflected in our current inability to recapitulate
the development of HSCs from pluripotent stem cells in vitro. In this
Review, we discuss what is known of human haematopoietic
development: the anatomical sites at which it occurs, the different
temporal waves of haematopoiesis, the emergence of the first
HSCs and the signalling landscape of the haematopoietic niche.
We also discuss the extent to which in vitro differentiation of human
pluripotent stem cells recapitulates bona fide human developmental
haematopoiesis, and outline some future directions in the field.
KEY WORDS: HSC, Human, Embryo, hPSC, Reprogramming
Introduction
In mammals, the first transient waves of blood cells arise in the yolk
sac (extra-embryonic haematopoiesis) and serve the immediate
needs of the growing embryo (Silver and Palis, 1997). They include
the most primitive wave, which consists mainly of large nucleated
erythrocytes that is rapidly followed by a second wave of erythro-
myeloid progenitors (EMPs) and lymphoid progenitors that
transiently seed the foetal liver (Böiers et al., 2013; McGrath
et al., 2015). The third wave, which includes self-renewing
haematopoietic stem cells (HSCs) that give rise to the permanent
adult haematopoietic system, emerges later inside the body of the
embryo (intra-embryonic haematopoiesis) in the aorta-gonad-
mesonephros (AGM) region, which is evolutionarily conserved in
many vertebrates (Medvinsky et al., 1993; Medvinsky and
Dzierzak, 1996). The process of HSC development in vertebrates
is driven by largely conserved, although not entirely identical,
molecular mechanisms (Medvinsky et al., 2011; Ciau-Uitz et al.,
2016). The endothelial origin of haematopoietic progenitors and
HSCs has been established by their emergence from the aortic
endothelial layer (Garcia-Porrero et al., 1995; Tavian et al., 1996;
Jaffredo et al., 1998), lineage tracing in vivo using genetic labelling
(Zovein et al., 2008; Chen et al., 2009; Bertrand et al., 2010; Kissa
and Herbomel, 2010) and observations of embryonic stem cells
(ESCs) differentiating in vitro (Eilken et al., 2009; Lancrin et al.,
2009). HSCs and non-self-renewing haematopoietic progenitor
cells that emerge in the AGM region are organised within intra-
aortic haematopoietic clusters (IAHCs). These bud predominantly
from the endothelial floor of the dorsal aorta, which accordingly co-
express endothelial and haematopoietic markers. The search for
markers that would accurately identify developing HSCs and
separate them from non-self-renewing progenitors is an important
goal towards understanding the mechanisms that underlie HSC
development (Rybtsov et al., 2014; Zhou et al., 2016). Important
events that occur downstream of HSC emergence include
colonisation and expansion of HSCs in the foetal liver and
subsequent lodging in the adult bone marrow.
Our current understanding of the mechanisms that drive HSC
development has come from analysis of various model organisms.
We do not intend here to provide detailed overview of non-human
models, as this extensive topic has been reviewed recently by us and
by others (Medvinsky et al., 2011; Kim et al., 2014; Ciau-Uitz et al.,
2016; Kauts et al., 2016; Robertson et al., 2016; Crisan and
Dzierzak, 2016). Owing to the high accessibility of model
organisms for experimentation and the genetic variability and
rarity of human embryonic material, the analysis of human
haematopoietic development has lagged behind these well-
established experimental models and for a long time was limited
to immunohistological and in vitro studies. More recently, the
development of highly efficient xenograft mouse models has
allowed human HSCs to be tested functionally (Shultz et al., 2012).
Despite the discovery of major commonalities between mouse and
human HSC development, significant differences remain that need
to be characterised in order to understand human HSC development.
Attempts to recapitulate haematopoiesis development via
directed differentiation of pluripotent stem cells (PSCs) – both
ESCs and induced PSCs (iPSCs) – have provided a valuable source
of information, although current protocols appear to replicate extra-
embryonic, yolk sac-like, rather than intra-embryonic, adult-like
haematopoiesis. Indeed, it may be for this reason that efforts to
generate bona fide HSCs from PSCs in vitro have not been
successful, undermining expectations for the generation of HSCs
for clinical needs. This, in turn, has stimulated the quest for
alternative methodologies, such as direct cell reprogramming
(Riddell et al., 2014; Sandler et al., 2014). In this Review, we first
discuss in vivo human haematopoietic development, focussing on
the different anatomical sites where haematopoiesis takes place, as
well as the molecular and functional characterisation of human
haematopoietic stem and progenitor cells as they emerge in a
spatiotemporal manner. Based on what is known regarding the
development of the human haematopoietic system, we consider the
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extent to which attempts to generate HSCs in vitro recapitulate in
vivo development, and discuss the prospect of generating true fully
functional HSCs in the dish – cells that would be suitable for
transplantations in clinical settings. The generation of HSCs in vitro
in the absence of genetic modifications would represent the
strongest indication that the key basic mechanisms that underpin
HSC development in the human embryo have become largely
understood.
The anatomy of haematopoietic development
In the mouse, developmental stages can be distinguished by
morphological changes occurring over less than a day. Human
embryo development, however, takes a significantly longer time.
Stages of human development, known as Carnegie stages (CS), are
defined by external morphological characteristics and normally
cover several days each (O’Rahilly and Muller, 1987). Staging
according to the Carnegie classification is more accurate than using
gestational age or crown-rump length, which is important when
analysing human HSC development (Ivanovs et al., 2013). For
consistency, where days post-conception (dpc) were used in original
publications, corresponding CS are presented in parallel in this
Review. Despite differences in developmental timescales,
substantial parallels between mouse and human haematopoietic
development can readily be observed (Fig. 1).
The yolk sac
The first wave of human haematopoiesis originates in the yolk sac, a
structure that develops differently in human and mouse. Whereas in
the mouse conceptus the yolk sac surrounds the body of the embryo,
in the human it develops in front of the embryo body in a balloon-
like form (Fig. 2A). Tight groups of ‘mesenchymal’ cells, of
mesoderm origin, that are adjacent to the endoderm, differentiate
into haematopoietic cells surrounded by endothelial cells, which
later remodel to form the yolk sac vascular plexus. Large primitive
nucleated erythrocytes represent the major haematopoietic output
from the yolk sac at CS 7-8 (16-18.5 dpc), with the occasional
presence of primitive macrophages and megakaryocytes (Bloom
and Bartelmez, 1940; Fukuda, 1973; Luckett, 1978). By CS 10
(21-22 dpc), the first primitive erythroblasts can be observed inside
the cardiac cavity, marking the onset of blood circulation, followed
by appearance of the first CD45+ (PTPRC+) cells, (Tavian et al.,
1999), similar to analyses in the mouse (Ghiaur et al., 2008).
Although a yolk sac EMP wave similar to the mouse has not been
formally characterised during human development, early studies
indicate that this wave may emerge in the human yolk sac during CS
13-15 (28-35 dpc) (Migliaccio et al., 1986).
The AGM region
The appearance of IAHCs on the ventral wall of the human dorsal
aorta in the AGM region, reported early last century (Minot, 1912),
marks the onset of the intra-embryonic, permanent adult
haematopoietic wave in the vertebrate embryo. Spatiotemporal
analysis revealed that IAHCs emerge at CS 13 (27 dpc), exclusively
at the floor of the embryonic dorsal aorta and disappear by CS 17
(39-42 dpc) (Tavian et al., 1996, 1999). By contrast, in the mouse
some IAHCs are also observed in the aortic roof (Taoudi and
Medvinsky, 2007; Taylor et al., 2010; Yokomizo and Dzierzak,
2010). In the human embryo, IAHC formation covers the pre-
umbilical area of the floor of the dorsal aorta and penetrates the entry
to the vitelline artery (Fig. 2B,C). Early mesoderm and the
endothelial compartment in early post-gastrulation embryos is
marked by KDR (also known as FLK1) expression (Cortés et al.,
1999). The endothelial lining of the human dorsal aorta upregulates
CD34, which later marks adult HSCs, from CS 9 (19 dpc) (Tavian
et al., 1996, 1999, 2001; Oberlin et al., 2002). By CS 13 (27 dpc),
the first CD34+CD45+ cells emerge in the pre-umbilical region of
the dorsal aorta, and their number reaches several hundred by CS 15
(33 dpc).
Although it is broadly accepted that IAHCs are formed from
mesodermal precursors through endothelial intermediates, in the
absence of direct tracking, various scenarios of IAHC formation can
be considered (Medvinsky et al., 2011) (see also ‘The endothelial
origin of human haematopoiesis’, below). Developing human
IAHCs sometimes appear to penetrate through the aortic endothelial
lining (Tavian et al., 1999). This could reflect a number of scenarios,
including ‘excessive’ endothelial-to-haematopoietic transition (EHT)
activity in situ, transendothelial cell migration towards the aortic
lumen into the bloodstream (Bertrand et al., 2005; Rybtsov et al.,
2011), or migration of EHT-undergoing cells in the opposite
direction, towards the venous system, as described in zebrafish
(Bertrand et al., 2010; Kissa and Herbomel, 2010). Expression of
angiotensin converting enzyme (ACE), which labels human foetal
liver HSCs (Jokubaitis et al., 2008), identifies scattered ACE+CD34−
cells beneath the dorsal aorta (Sinka et al., 2012). These have been
postulated to represent IAHC precursors, which upregulate CD34 and
after integration into the CD34+ endothelial lining form ACE+CD34+
IAHCs (Sinka et al., 2012). Identification of the exact migration
pathways during HSC specification in the mammalian AGM region
remains one of the least explored issues in the field.
The liver
The liver rudiment emerges as a diverticulum from the floor of the
embryonic gut at early CS 10 (21 dpc). From late CS 10 (22 dpc),
the liver rudiment contains primitive yolk sac-derived erythrocytes
and CD45+ cells, likely of monocytic/macrophage lineage. FromCS
13 (27-29 dpc), the liver is seeded by growing numbers of
CD34+CD45+ cells (Tavian et al., 1999), which likely represent
yolk sac-derived cells similar to mouse EMPs (McGrath et al.,
2015). Although direct experimental evidence is lacking, these
might be the cells that progressively replace primitive erythroblasts
in the human embryo bloodstream during liver colonisation fromCS
13-14 (30-33 dpc) onwards (Migliaccio et al., 1986). Concurrent
emergence of IAHCs and CD34+CD45+ cells in the liver at CS 13
suggests that some of these cells also represent colonisation of
the foetal liver by AGM-derived cells, despite a delay in
the appearance of HSCs in the liver (see ‘Spatiotemporal HSC
development in the early human embryo’, below). The liver remains
an important niche for haematopoietic differentiation and HSC
expansion until birth. Although some analysis of the developing
liver as the haematopoietic niche was conducted on the mouse, this
issue in human remains a largely unexplored territory.
The placenta
In the mouse placenta, definitive HSCs are detected at the same
developmental age as in the AGM region. For this reason, the
placenta is considered to be one of the HSC sources in the mouse
embryo (Gekas et al., 2005; Ottersbach and Dzierzak, 2005). At
least from week 5-6 of development, the human placenta contains
high numbers of CD34+ cells, represented by immature
CD34++CD45lo cells that lack CD38 and contain high colony-
forming units-culture (CFU-C) numbers, and CD34+CD45lo cells
committed to erythroid and myeloid differentiation containing
fewer CFU-Cs (Barcena et al., 2009). At this stage, the placenta is
also a site of extensive erythroid maturation: placental villi are
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enriched for primitive erythrocytes that express embryonic ζ-globin
in association with macrophages, which may facilitate their
enucleation (Van Handel et al., 2010). Although CD34+ cells
appear in the human placenta as early as at week 5 of gestation,
true HSCs can be detected there only after week 9 of gestation
or even later, as determined by xenotransplantation into
immunocompromised mice (Robin et al., 2009; Muench et al.,
2017). Although the CD34++CD45lo population that contains HSCs
is embedded within a vimentin-positive stromal environment or
rarely in close association with blood vessels (Muench et al., 2017),
localisation of the exact HSC fraction and their regulatory
microenvironment in the human placenta is currently unavailable.
The bone marrow
The development of the definitive bone marrow niche is closely
linked to the invasion of cartilaginous bone by blood vessels and
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Fig. 1. Chronology of human haematopoietic development. The first human haematopoietic cells, primitive erythroid cells and monocytes/macrophages are
produced in the yolk sac during CS 7 and 8 (16-18.5 days). With the onset of cardiac contractions at CS 10 (day 21) and blood circulation, yolk sac-derived
haematopoietic cells are disseminated throughout the developing embryo. CD34+CD45+ intra-aortic haematopoietic clusters appear in the vitelline artery and on
the ventral wall of the dorsal aorta at CS 13 (day 27). The clusters disappear by CS 16 (35-38 days). HSCs in the AGM region persist from CS 14 (day 30) until at
least CS 17 (day 42; latest stage tested). HSC activity in the AGM region precedes that in the yolk sac (CS 16; 35-38 days), liver (CS 17; 39-42 days) and placenta
(ca. 63 days). The haematopoietic lineage derives from a mesodermal precursor (grey) through the intermediate of the haematogenic endothelium before
expanding. For the sake of comparison, the step-wise emergence of mouse HSCs through immature haematopoietic precursors (pro-HSC, pre-HSC I, pre-HSC
II) is shown at the bottom of the figure. The existence of similar precursors in human haematopoietic development has not been functionally shown, which
is indicated by a question mark for human pro/pre-HSC. Red, bona fide HSCs; light red, haematopoietic lineages which may or may not be related to HSC
development; yellow, yolk sac haematopoietic differentiation. Fading of coloured bubbles to blue represents extinction of the process. White striped lines
represent a change in time scale (omission of several days for the mouse or weeks for the human).
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bone ossification. Vascular invasion facilitates seeding of bone
marrow with haematopoietic progenitors and HSCs. Bone marrow
formation arbitrarily marks the end of the human embryonic period
(CS 23; 56 dpc) (O’Rahilly and Muller, 1987). The initial
CD34−CD45+ haematopoietic cells that invade the cartilaginous
bone include mostly CD68+ monocytes/macrophages possibly
participating in chondrolysis. This is followed by colonisation
with CD34+CD45+ progenitors and HSCs (Charbord et al., 1996),
although the time of onset of HSC activity in the human bone
marrow remains unknown.
Understanding haematopoietic development through in vitro
approaches
A semi-solid in vitro (methylcellulose) assay allows an assessment
of the presence of CD34+ CFU-Cs in the early human embryo
(Tavian et al., 1999). However, this assay does not reveal the
potential of embryonic tissues to generate CFU-Cs or HSCs. In the
mouse, this issue was addressed by pre-culturing embryonic tissues
as explants to allow their further development ex vivo before
assessing their haematopoietic potential (Cumano et al., 1996;
Medvinsky and Dzierzak, 1996). This approach was adopted for
human studies and revealed that the human yolk sac and para-aortic
splanchnopleura (P-Sp; the precursor of the AGM region) isolated
prior to the onset of circulation at CS 10 (21 dpc; to exclude cross-
seeding) possess differing haematopoietic potentials (Tavian et al.,
2001). The yolk sac could generate only myeloid and natural killer
(NK) cells, whereas the P-Sp showed a broader spectrum of
haematopoietic differentiation including lymphoid B- and T-cell
lineages starting from CS 11 (24 dpc), suggesting that it could give
rise to multipotent haematopoietic progenitors in vivo (Tavian et al.,
2001). A subsequent study revealed that only the dorsal aorta and
not the yolk sac contained so-called long-term cobblestone area-
forming cells, which in bone marrow correlate with the presence of
HSCs (Oberlin et al., 2002). Although these results are consistent
with analyses in the mouse embryo, the human lympho-myeloid
precursors revealed in culture may not be equal to true HSCs.
Identification of the very few HSCs in the early human embryo
required development of a robust in vivo long-term repopulation
assay, which became possible only with the later advent of highly
receptive xenograft mouse models.
The endothelial origin of human haematopoiesis
Various non-human experimental models have shown that during
development haematopoietic cells emerge from the embryonic
endothelium (Jaffredo et al., 2000; de Bruijn et al., 2002; Bertrand
et al., 2010; Kissa and Herbomel, 2010; Chen et al., 2011).
KDR+CD34− cells observed in the early human embryo mark
mesodermal precursors that are likely to develop into endothelial
precursors (Cortés et al., 1999). CD34, which initially marks human
aortic endothelium, at CS 13 (27 dpc) has also been shown to label
IAHCs (Tavian et al., 1999). In a more recent study, CD34+CD45−
populations purified from CS 13-18 (28-44 dpc) dorsal aortas and
vitelline arteries were shown to give rise to myeloid and lymphoid
populations after co-culture with stromal cells (Oberlin et al., 2002).
This activity of the CD34+CD45− population (defined as
haematogenic endothelium) temporally correlated with IAHC
Fig. 2. Human embryonic haematopoietic tissues. (A) The location of the AGM region, yolk sac, liver, vitelline and umbilical arteries and placenta in a
CS 15 human embryo. The location of the amnion, eye, and upper and lower limbs are also indicated for reference. Note that HSCs at this stage are localised to the
AGM region and will appear in the yolk sac and liver slightly later. (B) Human IAHC development and the stage-specific spatial localisation of CD34+CD45+
cell clusters on the ventral wall of the dorsal aorta [indicated in red; modified from Tavian and Peault (2005)]. (C) VE-cadherin+CD45+RUNX1+ human IAHCs on
the ventral wall of the dorsal aorta of a CS 16 human embryo. Whole-mount antibody staining (left) and sagittal confocal section of the boxed area (right). The
largest clusters are usually localised close to the entry of the vitelline artery. Scale bars: 1 mm in A; 0.05 mm in C.
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formation, supporting the idea that clonogenic haematopoietic
progenitors reside within these structures. The CD34+CD45−
population, however, is heterogeneous and may contain not only
endothelial cells. Indeed, the endothelial-to-haematopoietic
transition (EHT) is a multistep maturation process, which includes
cell intermediates fully committed to the haematopoietic fate
(Taoudi et al., 2008; Medvinsky et al., 2011; Rybtsov et al., 2014).
In the mouse embryo and differentiating ESCs, the earliest
haematopoietic progenitors express the haematopoietic marker
CD41 (ITGA2B), and only later become CD45+ (Ferkowicz
et al., 2003; Mikkola et al., 2003; Eilken et al., 2009; Lancrin
et al., 2009). Similarly, the developing mouse HSC lineage
sequentially upregulates CD41, CD43 and finally CD45, which
together define the different stages of HSC maturation (Rybtsov
et al., 2014). Importantly, although these cell intermediates express
perhaps the most specific endothelial marker, VE-cadherin
(cadherin 5), they are devoid of endothelial activity and are fully
committed to the haematopoietic fate. During human ESC
differentiation in vitro, CD43 is the first marker of haematopoietic
specification (Vodyanik et al., 2006). Therefore, apart from
endothelial cells, the human AGM-derived CD34+CD45−
population might also include haematopoietic progenitors, which
could be responsible for haematopoietic activity in culture (Oberlin
et al., 2002). Although some molecular mechanisms underlying
EHT transition have been described (Ciau-Uitz et al., 2016), exactly
how haematopoietic progenitors and HSCs emerge from the
embryonic endothelium, especially in the human, remains an
issue for further investigation.
SpatiotemporalHSCdevelopment in theearly humanembryo
Human HSC development has been functionally evaluated through
transplantation into immunodeficient mice (see Box 1), which
represents a more stringent, long-term and robust assessment than in
vitro assays. All haematopoietic tissues known from mouse studies,
such as the AGM region, yolk sac, liver, umbilical cord and placenta
(Fig. 2A) have been assayed (Ivanovs et al., 2011). Short tandem
repeat analysis allowed for the discrimination between embryonic
and maternal cells, which might contaminate samples, especially in
placenta transplants. Examination of CS 12-17 (25-42 dpc) embryos
revealed the presence of HSCs predominantly in the AGM region.
Out of 11 experiments in which multipotent HSCs were detected in
the AGM region, nine showed the presence of HSCs solely in that
location. The first HSCs in the AGM region were detected as early
as at CS 14 (30-32 dpc) and persisted until at least CS 17
(39-42 dpc). In the yolk sac, HSCs were detected only after CS 16
(35-38 dpc), approximately 5 days later than in the AGM region. In
general, repopulation with yolk sac cells was significantly rarer than
with AGM region cells. A robust presence of HSCs in the liver is
generally detected later, from week 7-8 and the most potent subset
of liver HSCs still express VE-cadherin, reflecting their endothelial
origin (Oberlin et al., 2010; Ivanovs et al., 2011).
Although the appearance of HSCs in the mouse AGM region,
yolk sac, umbilical cord, liver and placenta occur almost
concurrently (Müller et al., 1994; de Bruijn et al., 2000;
Kumaravelu et al., 2002; Gekas et al., 2005; Ottersbach and
Dzierzak, 2005), their appearance in different locations in human
embryo is temporally resolved, owing to a more protracted
developmental period. Whereas in the mouse HSCs develop in
umbilical cord and placenta prior to liver colonisation (de Bruijn
et al., 2000; Gekas et al., 2005; Ottersbach and Dzierzak, 2005),
human umbilical cord and placenta at analogous stages (CS 14-17;
30-42 dpc) lack HSCs (Ivanovs et al., 2011). Only from week 9 of
development are HSCs reliably detected in the human placenta
(Robin et al., 2009), suggesting that the human placenta is a
secondary site for HSC development.
The aforementioned studies emphasise the importance of
functional in vivo assays for the analysis of HSCs. Although
immunohistological and in vitro studies suggested the appearance of
HSCs in the CS 13 (27-29 dpc) liver (Tavian et al., 1999),
transplantable HSCs appear there only after CS 17 (39-42 dpc)
(Ivanovs et al., 2011). Similarly, despite the presence of cells with
an HSC phenotype and CFU-Cs, week 5-6 human placentas lack
definitive HSCs (Barcena et al., 2009; Robin et al., 2009; Ivanovs
et al., 2011).
The exceptional regenerative potential of the first
human HSCs
Transplantation of AGM cells after CS 14 (30-32 dpc) into
immunodeficient mice results in long-term multilineage
haematopoietic engraftment, confirming the presence of definitive
HSCs (Ivanovs et al., 2011). As in the mouse, very few – normally
only one – HSCs emerge in the human AGM region, as
transplantation of cells from one human AGM into several
recipients usually results in one haematopoietically reconstituted
mouse (Fig. 3). Repopulation kinetics of human AGM region-
derived HSCs are significantly slower than their mouse counterparts.
By month 3 post-transplantation, haematopoietic chimerism reaches
approximately 1% of total leukocyte count in the recipient blood.
However, subsequent growth of human haematopoietic cells results
in up to 90% chimerism by month 8 in recipient peripheral blood and
bone marrow, which is accompanied by extensive generation of large
numbers (more than 300) of fully functional daughter HSCs, as
determined by re-transplantation into secondary recipients (Fig. 3)
(Ivanovs et al., 2011). For comparison, this significant production of
functional daughter HSCs exceeds the number required to prevent
bone marrow failure in patients after myeloablation (Catlin et al.,
2011). Computational analysis of the repopulation dynamics
suggested that adult human HSCs replicate every 40 weeks (Catlin
et al., 2011). However, amplification of human AGM-derived HSCs
from 1 to 300 in the recipient mouse over 6 months requires
Box 1. The history of the (NOD/SCID/Gamma) NSG mouse
line for haematopoietic transplantation assays
In the late 1980s, introduction of the antiprogestational compound
mifepristone for elective termination of early pregnancies (Vervest and
Haspels, 1985) made early intact human embryos available for research
purposes. At about the same time, severe combined immunodeficiency
(SCID) mice, which could accept human haematopoietic grafts, were
generated (McCune et al., 1988). These two factors largely defined
progress in functional analysis of human HSCs. As SCID mice often
immunoreject xenografts, they were backcrossed to non-obese diabetic
(NOD)mice, which are deficient in functional T, B and antigen-presenting
cells. For a long time, NOD/SCID recipient mice (Shultz et al., 1995) were
widely used to study human haematopoiesis in vivo. However, owing to
residual NK cell activity, haematopoietic engraftment of human HSCs is
attenuated, which especially affected experiments with low HSC
numbers. This, together with the short lifespan of these mice,
diminishes the utility of the model. To address this limitation, NOD/
SCID/Gamma (NSG) mice were engineered by introducing an additional
mutation in the IL2 receptor γ chain. Thesemice, which lack NK cells, live
for longer and support high-level human HSC engraftment (Shultz et al.,
2005). The NSG mice later permitted transplantation analysis of the first
humanHSCs emerging in low numbers in the AGM region (Ivanovs et al.,
2014, 2011).
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replication at least every 2-4 weeks, because transplanted HSCs also
generate differentiated blood cells. The proliferation of the first HSCs
in situ (in the embryo) may be even higher, given massive expansion
of HSCs in the foetal liver.
Achieving similar levels of immunodeficient mouse engraftment
with human umbilical cord blood (UCB) HSCs requires
considerably higher HSC doses, with 10-20 human UCB HSCs
giving approximately 40% repopulation by 8 months post-
transplantation (Notta et al., 2011). Re-transplantation of bone
marrow from recipients reconstituted with low numbers of UCB-
derived HSCs is inefficient and gives either low or no repopulation.
The unprecedented superior self-renewal capacity of AGM region-
derived HSCs is in line with observations that developmentally
younger foetal liver HSCs are more potent than HSCs from adult
bone marrow (Rebel et al., 1996; Holyoake et al., 1999).
Localisation and phenotype of the first human HSCs
In mice, IAHCs are localised predominantly to the ventral domain
of the dorsal aorta, correlating with the presence of functional HSCs
(Taoudi and Medvinsky, 2007). Similarly, the ventral domain of
the human AGM region is enriched for cells with an HSC
immunophenotype and function in transplantation studies,
suggesting that human HSCs also localised to IAHCs (Ivanovs
et al., 2014). However, although IAHCs disappear by CS 17 (35-
38 dpc), HSCs are still detectable at this stage indicating that
functional HSCs in the human AGM region do not entirely correlate
with the presence of IAHCs (Tavian et al., 1996, 1999). As in the
mouse, the number of IAHCs significantly exceeds the low numbers
of HSCs in the AGM (Ivanovs et al., 2011), suggesting that many
cells in human IAHCs could be nascent HSCs, that cannot yet be
detected by direct transplantation, as inferred from in vitro
modelling of mouse HSC development (Taoudi et al., 2008;
Rybtsov et al., 2011; Zhou et al., 2016). The development of a
similar in vitro co-culture approach for recapitulating human HSC
development has been unexpectedly challenging.
Xenotransplantation into immunodeficient mice revealed that the
earliest human HSCs emerging in the AGM region are CD34+VE-
cadherin+CD45+, consistent with an endothelial origin (North et al.,
2002; Taoudi et al., 2005; Ivanovs et al., 2014). This population
comprises 500-1000 cells and is uniformly labelled by other UCB
HSC markers (Majeti et al., 2007; Notta et al., 2011), which
together localise the first few definitive human HSCs to CD34+VE-
cadherin+CD45+KIT+THY1+endoglin+RUNX1+CD38−/loCD45RA−
cells (Ivanovs et al., 2014). Thus, compared with UCB from which
HSCs can be isolated with high purity (Notta et al., 2011),
identification of definitive HSCs within the AGM population is
inefficient, and remains a challenge. Phenotypic and quantitative
characterisation of the entire HSC hierarchy emerging in the human
AGM region is hampered by the lack of an experimental system to
identify immature human HSCs. Dissecting the composition of the
AGM-derived cell population that contains HSCs using additional –
and currently unknown – markers might provide further insights.
Human foetal liver and UCB HSCs could also be a source
of useful information for the identification of immature HSCs in
the AGM region (Notta et al., 2011; Prashad et al., 2015). In human,
the phenotypic identity of foetal liver HSCs is less defined than in
the mouse (Kim et al., 2006), although their main markers,
CD34+CD38−, are the same as those of UCB and bone marrow
HSCs (Majeti et al., 2007; Doulatov et al., 2012). GPI-80 (VNN2)
marks HSCs within the CD34+CD38−/loCD90 (THY1)+ foetal liver
population and could potentially be useful for enrichment of
developing HSCs from earlier pre-liver stages. Similarly, it would
be interesting to establish whether α6 integrin (also known as
CD49f), a marker for UCB HSCs, can be used for this purpose
(Notta et al., 2011).
The signalling landscape within the human AGM niche
HSC development is closely associated with the development
of the dorsal aorta and these two developmental programmes share
common signalling pathways, which have mainly been investigated
using model organisms. In various species, KDR/VEGF signalling
plays an important role in the formation of the dorsal aorta (Ciau-
Uitz et al., 2016). Groups of KDR+CD34− cells can be detected at
CS 10 (21 dpc) in the trunk mesoderm just before the onset of blood
circulation (Cortés et al., 1999). These cells could potentially be
considered as candidates for the definitive haemangioblasts
described in model organisms and in hPSC cultures (Kennedy
et al., 2007; Ciau-Uitz et al., 2016; Slukvin, 2016). By CS 14-15
(30-34 dpc), endothelial cells of the dorsal aorta and IAHCs co-
express KDR and its ligand VEGF (Marshall et al., 1999) and
upregulate transcription factors that are crucially important for
haematopoietic development in IAHCs, such as RUNX1 (also
known as AML1), c-myb (MYB), SCL (TAL1), GATA2 and
GATA3 (Tavian et al., 1996; Labastie et al., 1998; Marshall et al.,
1999; Ivanovs et al., 2014).
AGM region 
Single cell suspension 
1/75th 
1/150th 
1/300th 
 
Secondary transplantation 
Primary transplantation 
Fig. 3. Quantitative analysis of the regenerative potential of human AGM
region-derived HSCs. A cell suspension of dissociated AGM region tissue
repopulated the haematopoietic system of just one primary recipient NSG
mouse, indicating the presence of only one HSC in this tissue. Successful
engraftment and thus the presence of a bona fide HSC is indicated by
a red oval; non-HSC cells are indicated by black ovals. Six months after
transplantation, the bone marrow (BM) of the primary recipient was
transplanted in serial dilutions into secondary recipients. Repopulation of all
recipients indicated that the original AGM-derived HSC generated no fewer
than 300 daughter HSCs (Ivanovs et al., 2011).
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Ventral polarisation in IAHC and HSC development in model
organisms is at least partly driven by spatial asymmetry of molecular
signalling in the AGM region (Wilkinson et al., 2009; Souilhol
et al., 2016), suggesting similar mechanisms in human. From CS 13
(28 dpc), BMP4 expression is observed ventrally in a thin
subendothelial mesenchymal layer of the dorsal aorta, which
transiently expands and subsequently disappears by CS 16 (38 dpc).
At this stage, functionally defined HSCs are still present in the
AGM region (Ivanovs et al., 2011). BMP4 is a negative regulator of
HSCmaturation: although it is involved in the formation of the HSC
niche, its direct action on HSCs is likely limited by BMP antagonists
(Souilhol et al., 2016). Notably, BMP4 can induce expression of
tenascin C and fibronectin (Molloy et al., 2008), two extracellular
matrix molecules that are also ventrally polarised in the human
AGM region (Marshall et al., 1999). Tenascin C promotes
haematoendothelial development of hESCs (Uenishi et al., 2014)
and its deficiency impairs mouse bone marrow cultures, which can
be rescued by fibronectin (Ohta et al., 1998). TGFβ, another well-
known modulator of the extracellular matrix, is expressed in close
proximity to IAHCs at the same time as BMP4 expression is
downregulated. It has been proposed that TGFβ could participate in
rearrangement of the niche and restriction of HSC expansion prior to
foetal liver colonisation (Marshall et al., 2000).
Signalling through KIT is important for HSC maturation and its
ligand, SCF (KITL in mouse; KITLG in human), is ventrally
polarised in the mouse AGM region (Rybtsov et al., 2014; Souilhol
et al., 2016). KIT is expressed in IAHCs and in the first functional
HSCs emerging in the human embryo (Labastie et al., 1998;
Ivanovs et al., 2014). BMP4 can upregulate KIT in various tissues
and, through upregulation of KIT in human aortic endothelium, it
may potentially facilitate HSC initiation (Marshall et al., 2007).
However, further HSC development may require suppression of
BMP4 signalling, as described in the mouse (Souilhol et al., 2016).
FLT3, which marks mouse embryonic HSC precursors (Boyer et al.,
2011), and its ligand are also expressed in IAHCs and surrounding
endothelium, and may be involved in human HSC maturation
(Marshall et al., 1999).
Adhesion and migration
HSC development is associated with cell migration and IAHCs are
marked by a range of adhesion molecules that potentially play a role
in this process. CD34 and its receptor L-selectin (CD62L; SELL)
are involved in cell adhesion processes including lymphocyte-
endothelial interactions (Rosen, 2004), and are expressed in
human embryonic endothelium, IAHCs and functional HSCs
(Tavian et al., 1996; Ivanovs et al., 2014). The first lineage-
restricted haematopoietic marker, SPN, appears during hPSC
differentiation (Vodyanik et al., 2006) and can mediate adhesion
through E-selectin receptor (SELE) (Matsumoto et al., 2005). CD34
and CD43 can cooperatively define adhesive behaviour of
haematopoietic cells (Drew et al., 2005). Other surface molecules
involved in cell adhesion – ALCAM, VE-cadherin, CD44, CD164
and VCAM1 – are also expressed in IAHCs, endothelial cells of the
dorsal aorta and sometimes the mesenchymal cells underneath
IAHCs (Cortés et al., 1999;Watt et al., 2000;Marshall, 2006; Ivanovs
et al., 2014). Given the role of the TNF/lymphotoxin/NFκB pro-
inflammatory pathway in early HSC development described in model
organisms (Espín-Palazón et al., 2014; Li et al., 2014) and its impact
on VCAM1, L- and E-selectin expression (Suna et al., 2008), it is
conceivable that complex and finely regulated adhesion dynamics
play important roles in human HSC development. However, it is
likely that additional signalling pathways described in other model
organisms (Ciau-Uitz et al., 2016) also play a role in human HSC
development. Modelling HSC development in vitro using PSCs and
other approaches could shed light on this issue.
Recapitulation of humanhaematopoietic development using
pluripotent stem cells
This section examines parallels between the in vitro haematopoietic
differentiation of hPSCs and aspects of haematopoietic development
in the human embryo. Rather than replicating recent reviews that
comprehensively discuss protocols for the differentiation of hPSCs
intoHSCs or progenitors (Ditadi et al., 2016; Slukvin, 2016;Wahlster
and Daley, 2016), we have structured this section to highlight the
extent to which in vitro differentiation reflects human haematopoietic
development (Fig. 4). We argue that ongoing efforts to generate
HSCs from PSCs in vitro are both informed by and add to our
understanding of the signalling events that underpin in vivo human
haematopoietic development.
Mesoderm induction and patterning
In the mammalian embryo, ingression of cells through the primitive
streak during gastrulation generates mesoderm, which colonises the
yolk sac (extra-embryonic mesoderm) and intra-embryonic sites
including paraxial, intermediate and lateral plate mesoderm (Tam
and Behringer, 1997). Whereas extra-embryonic mesoderm gives
rise to transient yolk sac haematopoiesis, lateral plate mesoderm
adjacent to the paraxial mesoderm (the splanchnopleura) forms
bilateral mesodermal strips that converge to the midline where they
coalesce to form the dorsal aorta. The growth factors involved in
mesoderm specification, dorsal aorta formation and haematopoietic
development include members of the FGF, WNT, TGFβ, retinoic
acid, Hedgehog and Notch signalling pathways (Lawson et al.,
2001; Gering and Patient, 2005; Chanda et al., 2013; Lizama et al.,
2015; Ciau-Uitz et al., 2016).
In culture, as in vivo, mesoderm induction and pattering is
mediated by the cooperative actions of highly conserved FGF,
BMP4, activin and canonical WNT signals (Schier and Shen, 2000;
Kimelman, 2006; Nostro et al., 2008; Woll et al., 2008; Wang and
Nakayama, 2009; Bernardo et al., 2011; Yu et al., 2011). Mesoderm
patterned to a haematopoietic fate is marked by the expression of
primitive streak genes, such as the transcription factor genes
brachyury (T), MIXL1, FOXF1, as well as cell surface receptors
KDR and PDGFRA (Davis et al., 2008; Ditadi et al., 2016; Slukvin,
2016). An early study showed that the most efficient production of
haematopoietic cells resulted from the exposure of the emerging
mesoderm to activin and BMP4 signalling (Nostro et al., 2008),
analogous to the posterior primitive streak from whence the first
yolk sac haematopoietic progenitors are derived. Arguably, this
might explain why the haematopoietic output also resembled that
of the yolk sac and did not include long-term HSCs. It was only
later that a series of studies shed light on the role of mesoderm
patterning for both the suppression of primitive haematopoiesis
and for the support of definitive haematopoietic lineages.
Following an initial period of BMP4-based mesoderm induction,
brief inhibition of activin (Kennedy et al., 2012), or provision of a
WNT agonist (Gertow et al., 2013) were sufficient to inhibit the
erythroid-biased primitive programme. Importantly, activin
inhibition (Kennedy et al., 2012), WNT stimulation (Sturgeon
et al., 2014) or a combination of the two (Ng et al., 2016) from days
2-4 of in vitro differentiation also resulted in a bias towards
definitive haematopoietic lineages, as defined by the capacity to
generate T lymphocytes (Kennedy et al., 2012; Sturgeon et al.,
2014).
2329
REVIEW Development (2017) 144, 2323-2337 doi:10.1242/dev.134866
D
E
V
E
LO
P
M
E
N
T
The selective expression of HOXA genes in human foetal liver
and UCB-derived haematopoietic progenitor and stem cells clearly
distinguished them from PSC-derived haematopoietic progenitors
generated using conventional mesoderm induction protocols
(Dou et al., 2016; Ng et al., 2016). HOX genes mark axial
position during development and are first expressed at the
primitive streak stage (Deschamps and van Nes, 2005).
Therefore, it was relevant that activin inhibition and WNT
stimulation during mesoderm patterning, alone and in
combination, increased the expression of the CDX genes,
leading to sustained expression of their target HOXA genes and
more closely mimicking the HOXA expression signature seen in
foetal liver and cord blood cells (Ng et al., 2016). These data
support the premise that allocation of cells to extra- and intra-
embryonic haematopoietic fates is initiated during mesoderm
patterning, and that this is reflected in the selective expression of
HOXA genes in definitively patterned mesoderm (Fig. 4).
The generation of yolk sac-like haematopoietic lineages
The emergence of FGF2- and VEGF-dependent blast colonies from
BMP4-induced mesoderm after 2-4 days of differentiation marks
the onset of haematopoiesis in human hPSC cultures (Kennedy
et al., 2007; Davis et al., 2008; Vodyanik et al., 2010). As well as the
surface markers KDR and PDGFRα, blast colony-forming cells
(BL-CFCs) also express the apelin receptor (Vodyanik et al., 2010;
Choi et al., 2012; Yu et al., 2012), and CD235a (glycophorin A)
(Sturgeon et al., 2014). As in the mouse (Huber et al., 2004), human
blast colonies give rise to haematopoietic, endothelial and smooth
muscle lineages (Yu et al., 2012). Haematopoietic differentiation of
blast colonies is limited to primitive erythrocytes, megakaryocytes
and macrophages, and, as in the mouse (Lancrin et al., 2009),
probably occurs via a haematogenic endothelial cell precursor.
Further differentiation of hPSCs along a yolk sac-type path can be
achieved by co-culture with mouse OP9 stromal cells (Vodyanik
et al., 2006), as embryoid bodies (Pick et al., 2007; Nostro et al.,
2008) or monolayer cultures (Uenishi et al., 2014) in serum-free
media supplemented with growth factors, usually including VEGF,
SCF and FGF2. Endothelial and haematopoietic cell surface markers
are sequentially acquired, starting with CD34 after 4-6 days, and
followed by CD43 at day 6-8, the expression of which first
distinguishes haematopoietic from endothelial lineages (Vodyanik
et al., 2006). The formation of these blood cells from an endothelial
intermediate indicates that the endothelial-to-haematopoietic
transition is a common mechanism for blood formation both in the
embryo and in differentiating hPSCs and is not limited to a particular
developmental stage.
The CD34+CD43+ haematopoietic progenitors give rise to a
broad range of erythroid and myeloid lineages (Choi et al., 2012;
Kennedy et al., 2012; Ng et al., 2016), reminiscent of the broad
potential of the yolk sac-derived erythro-myeloid progenitor (EMP)
described in the mouse that transiently seeds the foetal liver
(McGrath et al., 2015). Although EMP-type haematopoiesis has not
been formally characterised in human embryos, kinetic studies
report a rapid transition of clonogenic cells from the yolk sac to the
foetal liver at around 5 weeks of gestation (Migliaccio et al., 1986).
Given that at this time the human foetal liver does not yet possess
repopulating ability (Ivanovs et al., 2011), the cells seeding the early
foetal liver are likely to include yolk sac-derived EMPs, and the yolk
sac-like erythroid and myeloid cells derived from hPSCs may be
their human in vitro equivalent. Whether these EMP-type cells are
defined as a second ‘primitive’ or a first ‘definitive’ haematopoietic
wave is somewhat moot. For the moment, the descriptor ‘EMP’may
be sufficient. We do point out, however, that in contrast to
haematopoietic cells derived from the AGM region, foetal liver or
HOXA+HOXA– 
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Yolk sac EMPs
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Foetal
erythroid and
myeloid cells
T lymphocytes 
Pre-HSCs
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B-1 and B-2
progenitors 
T progenitors 
Multipotent
myeloid
progenitors
Pluripotent
stem cells
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d2-4 SB
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Macrophages
Yolk sac-like HE
d7-9 AGM EMPs
Extra-embryonic
haematopoiesis
AGM-like HE
d9-18
Foetal
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Fig. 4. Model of in vitro haematopoietic
differentiation from human pluripotent stem
cells. Separation between extra-embryonic, yolk
sac-like haematopoiesis (blue shading and arrows)
and intra-embryonic AGM-like haematopoiesis
(red shading and arrows) initially occurs at the
time of mesoderm patterning [days (d) 2-4 of
differentiation]. WNT agonists (CHIR99021,
denoted CHIR) and activin antagonists
(SB431542, denoted SB) orchestrate this switch,
although other molecules, such as retinoic acid,
may also play a role. A key difference between the
extra- and intra-embryonic programmes is the
expression of a specific combination of HOXA
genes that is restricted to the endothelia and
haematopoietic progenitors of intra-embryonic
haematopoiesis. The extra-embryonic programme
generates blast colony-forming cells (BL-CFCs),
which are suppressed in the intra-embryonic
programme. In both programmes, haemogenic
endothelia (HE) generate erytho-myeloid
progenitors (EMPs) and T lymphocytes. Thus far, B
cells have been generated from an extra-embryonic
type protocol although it is anticipated that similar B
cells can be derived from AGM-like HE (dashed red
arrow). The asterisk indicates that it is not known
whether the B cells generated from hPSCs are B-1
or B-2 type. The intra-embryonic AGM-like HE
yields cells that have pre-HSC characteristics.
Although HSCs and their progeny are predicted
(greyed arrows and images), these have yet to
be formally shown.
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other embryonic sites, hPSC-derived EMP-like cells do not express
HOXA genes (Dou et al., 2016; Ng et al., 2016).
The generation of AGM-like haematopoietic lineages from
haematogenic endothelium
As discussed above, the appearance of IAHCs in the AGM region,
which arise from a transient haematogenic endothelium in the dorsal
aorta, predicts the emergence of the first stem cells that acquire
repopulating activity in the vertebrate embryo. In contrast to
non-haematogenic vascular cells, hPSC-derived haematogenic
endothelium lacks expression of CD73 (NT5E) (Choi et al., 2012;
Ditadi et al., 2015), CXCR4 and DLL4 (Ditadi et al., 2015). Also,
both mouse (North et al., 1999; Thambyrajah et al., 2016) and
human (Choi et al., 2012; Ng et al., 2016) haematogenic
endothelium are distinguished by their expression of the key
transcription factors RUNX1 and GFI1, which are required for the
endothelial to haematopoietic transition. Interestingly, hPSCs
differentiated with a protocol that induces HOXA gene expression
produce SOX17-expressing endothelial cells that bear similarity at
the transcriptional level to developing dorsal aorta endothelium, and
a SOX17dull haematogenic endothelial population that efficiently
generates haematopoietic cells (Ng et al., 2016). The low level of
SOX17 in haematogenic cells is consistent with literature reporting
the downregulation of SOX17 during the EHT (Clarke et al., 2013;
Nobuhisa et al., 2014). Similarly, single-cell analysis of hPSC-
derived cells documented a downregulation of SOX17 at the EHT
point (Guibentif et al., 2017).
It has not been possible to identify cell surface markers that
distinguish true or ‘definitive’ AGM-derived HSCs from yolk sac-
type, non-engrafting haematopoietic progenitors (Ditadi et al.,
2016; Slukvin, 2016). For this reason, considerable attention has
been paid to the generation of lymphocytes from hPSCs in vitro,
arguing that these lineages represent definitive haematopoiesis and
may indicate culture conditions that support the development of
AGM-like HSCs. Many laboratories have generated T cells from
hPSCs, in a Notch-dependent fashion, from endothelial precursors
present at 7-9 days of differentiation (Timmermans et al., 2009;
Kennedy et al., 2012; Uenishi et al., 2014; Ditadi et al., 2015; Dou
et al., 2016; Ng et al., 2016). The dependence of AGM-type, but not
yolk sac-type haematopoiesis on Notch signals in the mouse embryo
(Kumano et al., 2003; Hadland et al., 2004) has been used to further
strengthen the case that the hPSC-derived T cells are progeny of an
intra-embryonic haematopoietic progenitor. An important caveat,
however, is the realisation that, in the mouse, both T- and B-cell
potential is present in the pre-AGM stage yolk sac (Yoshimoto et al.,
2011, 2012; McGrath et al., 2015). The dependence of human yolk
sac-derived EMP or lymphoid cells on Notch signals is not known.
Unlike the relative ease in which T cells can be derived, B-cell
development from hPSCs has been infrequently reported. One
laboratory described the generation of cells with a CD19+CD10
(MME)+ pre-B-cell phenotype, some of which matured to surface
IgM+ immature B cells (French et al., 2015).
To place this in context, during mouse development there are
several waves of B-cell production (Herzenberg and Herzenberg,
1989). The first innate type B cells, called B-1 cells, arise
independently from haematogenic endothelia in both the yolk sac
and the AGM region, prior to HSCs, and seed the foetal liver
(Yoshimoto, 2015). Subsequent waves of HSC-derived B-1 and
adaptive B-2 lymphocytes arise later in the foetal liver (Yoshimoto,
2015) and a wave of predominantly HSC-derived B-2 lymphocytes
emerges in the bone marrow (Montecino-Rodriguez and Dorshkind,
2012). The identification of B-1 lymphocytes in humans (Rothstein
and Quach, 2015), and their observation in the 10-11 week foetal
liver (Bueno et al., 2016), argues for conservation of the innate
immune system between species. Given that human B-1 cells differ
immunophenotypically from B-2 lymphocytes (Rothstein and
Quach, 2015), it should therefore be possible to discern whether
B cells derived from human hPSCs include B-2 cells, and are thus
unequivocally descended from HSCs.
The pattern of globin chain expression by hPSC-derived erythoid
cells has also served as an indicator of developmental stage.
Erythroid cells differentiated from human PSCs usually express
ε- and γ-globins (Chang et al., 2006; Lu et al., 2008; Hatzistavrou
et al., 2009; Dias et al., 2011), although prolonged culture in human
plasma or on stromal layers has yielded predominantly γ- or γ- and
β-globin-expressing cells (Qiu et al., 2008; Lapillonne et al., 2010;
Yang et al., 2014; Fujita et al., 2016). Importantly, the switch to
β-globin synthesis occurs perinatally, and thus is not expected at
the AGM or foetal liver stages of haematopoiesis. Rather,
focus is on the anticipated downregulation of embryonic ε- and
ζ-globins that signifies exit from primitive haematopoiesis. As a
further complication, yolk sac EMP-derived erythroid precursors in
mice carrying a single copy of the human β-globin locus
downregulate ε-globin and express low levels of β-globin when
matured in vitro (McGrath et al., 2011). As with the generation of
lymphoid cells, these findings indicate that it is not easy to exclude
yolk sac EMP haematopoiesis as a source of erythroid cells that
appear to derive from foetal liver because they have suppressed
embryonic globins.
Finally, although EMPs are traditionally associated with the yolk
sac, cells with a similar restricted developmental capacity could
conceivably derive from the AGM haematogenic endothelium
also. Consistent with this hypothesis, clonogenic progenitors
(approximately 90 colonies per embryo) are present in the VE-
cadherin+CD45+ population in the human AGM region, the same
fraction harbouring less frequent pre-HSCs and HSCs (Ivanovs
et al., 2014). These clonogenic cells might also seed the early foetal
liver, and might only be distinguishable from yolk sac-derived
EMPs by their expression of HOXA genes. Although further
experiments will be required as proof, there is support for this idea in
a recent report of ε- to γ-globin switching and downregulation of ζ-
globin in clonogenic cells derived from HOXA+ cultures (Ng et al.,
2016).
Transcriptional comparisons of cells emerging from hPSC-
derived HOXA+ haematogenic endothelium and AGM-derived
stem progenitors has revealed a high degree of similarity across a
broad range of haematopoietic cell surface markers, transcription
factors and signalling molecules (Ng et al., 2016). Nevertheless,
the hPSC-derived progenitors lack some essential characteristics
that enable long-term haematopoietic repopulation. Although
mesoderm patterning with modulation of WNT and activin
signals increases HOXA expression, the pattern of expression in
the hPSC-derived progenitors differs subtly from that observed in
human AGM samples, with reduced expression of anterior HOXA
genes and elevated levels of the most posterior HOXA genes
(Ng et al., 2016).
Alternative strategies to explore human haematopoietic
development
Teratoma formation as a model for human HSC development
In vivo teratoma formation may offer valuable insights into the
generation of transplantable HSCs from hPSCs. Teratomas, which
contain derivatives of all three germ layers, can be formed after
ectopic engraftment of PSCs into a host animal. The mixture of cell
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types in these tumours can preserve some developmentally
important inductive interactions, leading to the formation of
disorganised tissues and organs, including bone marrow (Hentze
et al., 2009; Amabile et al., 2013). Teratomas formed from hPSCs
engrafted into immunodeficient mice, in some cases, generate
human CD45+ cells that home to bone marrow, circulate in the
recipient peripheral blood and colonise lymphoid tissues (Amabile
et al., 2013; Suzuki et al., 2013). Transplantation of total bone
marrow or sorted human CD34+CD45+ bone marrow cells
from primary into secondary recipients shows donor-derived
multilineage peripheral blood chimerism, comparable to UCB
repopulation (Amabile et al., 2013; Suzuki et al., 2013). Teratoma-
derived B and T cells appear functionally normal, and erythrocytes
express adult haemoglobins, which is not usually achievable during
in vitro hPSC differentiation. It is conceivable that in vivo teratoma
formation might more faithfully recapitulate some of the processes
that occur during embryo development and, in some cases, this
could include the specification of an AGM-like region and lead to
the production of HSCs. However, an extended period of
observation is required to determine whether these HSC-like cells
have a truly long-term haematopoietic potential (Ivanovs et al.,
2011; Notta et al., 2011).
Direct cell lineage conversion: programming and reprogramming
to blood
Although enforced gene expression has been shown to be a
powerful tool for altering cell fate for several decades (Davis et al.,
1987; Kulessa et al., 1995), the real boost to the generation of blood
cells using this approach was precipitated by reprogramming studies
in which fibroblasts were reverted back to pluripotency using four
transcription factors (Takahashi and Yamanaka, 2006; Pereira et al.,
2012). These studies spawned quests for combinations of
transcription factors, overexpression of which could generate
clinically relevant cell types, including HSCs. Groups chose
either ESCs (Kyba et al., 2002; Elcheva et al., 2014), human
endothelial cells (Sandler et al., 2014), haematopoietic cells
(Doulatov et al., 2013) or fibroblasts (Pereira et al., 2013; Batta
et al., 2014) as the starting material. Comparative transcriptomics of
HSC and progenitor cell populations often provided lists of
candidate factors to overexpress. Although many of the factors
used in reprogramming studies have previously been implicated in
developmental haematopoiesis, their true ‘haematopoietic potency’
becomes unveiled when they are expressed in a foreign cellular
context, such as when reprogramming fibroblasts (Pereira et al.,
2013; Batta et al., 2014) or undifferentiated PSCs (Elcheva et al.,
2014; Vereide et al., 2014) (see Fig. 5 for details).
Using an hPSC differentiation model, the potency of two pairs of
transcription factors, ETV2/GATA2 and GATA2/SCL, has been
shown in activating pan-myeloid or erythro-megakaryocytic
programmes, respectively (Elcheva et al., 2014). These results
reflect the importance of these factors as haematopoietic fate-
determining transcription factors (Elcheva et al., 2014). Although
this system failed to generate long-term repopulating cells, it is a
powerful tool for the dissection of haematopoietic developmental
pathways. In separate studies, a HOXA9/ERG/RORA/SOX4/MYB
combination of transcription factors was identified by comparing a
human HSC-enriched population with more mature progenitors
from UCB (Doulatov et al., 2010; Laurenti et al., 2013).
Overexpression of this combination of transcription factors in
hPSC-derived haematopoietic progenitors conferred transient
in vivo engraftment capacity (Doulatov et al., 2013). The data
suggested that HOXA9, ERG, RORA, SOX4 and MYB belong to
the same molecular regulatory network; this is supported by the
observation that HOXA9 occupies Erg, Sox4 and Myb promoters
(Huang et al., 2012). The interest in analysis of HOX genes reflects
their strong positive impact on expansion of mouse bone marrow
HSCs (Antonchuk et al., 2002; Argiropoulos and Humphries,
2007). Moreover, collinear activation of HOX genes is involved in
temporal regionalisation of the mesoderm (Iimura and Pourquié,
2006), which may underlie functional differences in sequentially
emerging haematopoietic waves. For example, HoxB4
overexpression along with adjusted Notch signalling confers
multilineage long-term repopulation ability to mouse ESCs (Lu
et al., 2016). Downregulation of HOXA5 and HOXA7 in human
foetal liver HSCs supresses their capacity to self-renew and
repopulate NSG recipients. Although, forced expression of
HOXA5, HOXA7 and HOXA9 alone or in combination in
HOXA-negative hPSC-derived progenitors was insufficient to
convert the progenitors to HSCs (Dou et al., 2016), a recent study
reported a greater degree of success by using a larger cohort of genes
(Sugimura et al., 2017). Induced expression of seven transcription
factors, notably including three HOXA genes, successfully
converted hPSC-derived haematogenic endothelium into long-
term repopulating HSCs (Sugimura et al., 2017). Finally, expression
of four transcription factors (FOSB, GFI1, RUNX1 and SPI1) in
human umbilical vein and dermal microvascular endothelial cells,
or in adult mouse endothelial cells, were also sufficient to generate
immunocompetent HSCs (Sandler et al., 2014; Lis et al., 2017). In
all these studies, using transcription factors to manipulate cellular
identity has provided insights into the regulation of normal
haematopoietic development (Fig. 5). For example, successful
reprogramming of fibroblasts into blood allowed, through obtaining
a molecular signature, identification of precursors of long-term
repopulating cells in the mouse placenta (Pereira et al., 2016).
Future directions and challenges
Understanding the development of the human haematopoietic
system is of fundamental biological and clinical importance.
Various haematopoietic diseases originate prenatally (Hunger
et al., 1998; Greaves, 2005; Hong et al., 2008; Roy et al., 2012;
Barrett et al., 2016), and oncogenic mutations in developing
haematopoietic progenitors or stem cells can lead to pre-leukaemic
changes that may not be manifested if the oncogene is activated in
the adult counterparts (Barrett et al., 2016). The molecular
mechanisms that regulate development and maintenance of
haematopoietic progenitor and stem cells in the embryo differ
significantly from those in the adult, and the functional
heterogeneity that appears within the emerging HSC population
during development further complicates our understanding of HSC
regulation (Copley et al., 2012; Crisan et al., 2015; Beaudin et al.,
2016). Although the impetus to study human haematopoietic
development is clear, poor availability and heterogeneity of human
embryonic material makes the analyses challenging. Direct
extrapolation of results obtained from model organisms is not
always appropriate owing to species-specific differences, although
major genetic networks and sites of haematopoiesis are significantly
conserved. Furthermore, for ethical and practical reasons, studying
the period of early implantation in the human is extremely difficult.
Thus, this highly relevant developmental stage remains largely
inaccessible and so cannot inform protocols for derivation of HSCs
from PSCs. Additionally, until recently, PSC differentiation was
biased towards transitory yolk sac haematopoiesis, resulting in the
failure of this in vitromodel to fully inform us of the mechanisms of
HSC development in vivo. Thus, deficiency in our in vivo
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knowledge has not yet been compensated for by information from
the in vitro system, and vice versa.
In our opinion, two approaches may be taken to address this
problem. Notwithstanding their limitations, it is important to continue
to use model organisms, which remain virtually unrestricted resources
in which to pursue detailed analyses of HSC development. Although
not free from ethical and practical considerations, research using non-
human primates may also provide valuable information that will help
to bridge the evolutionary gap between the mouse and human
(D’Souza et al., 2016).
A second approach is the continued use of reprogramming to
investigate key determinants of cell fate. Although reprogramming
seems like a bold approach to generating cells of interest, it could
potentially inform us about events that occur in vivo, provided that it
goes beyond describing acquisition of markers and extends to
functional characteristics. Research in this direction should aim to
identify the best cell sources and factors for producing normal,
functional HSCs. To date, the selection of genes for haematopoietic
reprogramming has been based on genes known to be essential for
haematopoietic development and genes that are differentially
expressed in bone marrow/foetal liver/UCB HSCs compared with
progenitor cells. However, the genes that drive the formation of the
first exceptionally potent HSCs that emerge in the human AGM
region (Ivanovs et al., 2011) remain unknown. Identification of
these genes in human requires more detailed reconstruction of the
developing HSC hierarchy, which is currently limited by lack of an
appropriate experimental system in human, but could be facilitated
by further in-depth analysis of model organisms. Although the data
show a lack of definitive HSCs in human placenta and large extra-
embryonic arteries, they should not be excluded from consideration
as they could harbour immature HSCs.
The presence of one or more transgenes in the genome of
reprogrammed human HSCs represents a clinical risk, and further
makes it difficult to assess the entire scale of molecular changes in
the reprogrammed cells. Reprogramming methods that do not
involve transgene integration, such as non-integrating vectors and
RNA, will therefore be highly desirable. Whether this approach,
which has proved suitable for iPSC generation, will work for
reprogramming into HSCs will depend on the activation of crucial
endogenous genes that act as ‘molecular switches’ to produce a
phenotypically stable cell type, long after the non-integrating factors
are degraded or diluted. This is particularly important for conferring
stemness to progenitor cells, but so far it is not clear whether this
approach will be successful. Ultimately, the safest HSCs generated
in the dish would likely be genetically unaltered cells, produced
by exposure to external factors equivalent to the embryonic cues
that drive HSC development. Here, the bottleneck seems to be
identifying the combinations of soluble and cell-based factors and
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Fig. 5. Programming and reprogramming towards haematopoietic fate. In vitro generation of haematopoietic cells usually occurs via either directed
differentiation of PSCs (green arrows), or via transcription factor-based reprogramming of a variety of different starting cell types (blue boxes). These include
ESCs and iPSCs, human umbilical vein endothelial cells (HUVECs), adult fibroblasts, haematogenic endothelium cells, and pro-B cells. Transcription factor
combinations used for reprogramming as well as the direction of reprogramming are shown in red (human) and purple (mouse). ETO is also known as RUNX1T1.
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inhibitors that will produce bona fide long-term repopulating human
HSCs and again, analysis of mouse and other model organisms as
well as reprogramming studies may shed light on this problem. The
generation of reporter hPSC lines will continue to be a powerful
methodology for analysing human HSC development (Rafii et al.,
2013; Jung et al., 2016; Ng et al., 2016). Ultimately, the depth of
our understanding of human HSC development will be measured by
our ability to faithfully recapitulate in vitro the embryonic pathway
that leads to HSC formation. This is what will pave the way to
informative in vitro modelling of childhood haematological
pathologies, and to the robust generation of bona fide HSCs for
possible clinical use.
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